Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump’s Psychedelic Research Order

Key Takeaways

• Shares of DFTX climbed more than 13% during premarket hours following President Trump’s Executive Order promoting psychedelic medicine research for mental health disorders
• The presidential directive instructs the FDA to expedite research and regulatory pathways for psychedelic-based therapies, including suicide prevention applications
• Definium’s Chief Executive Officer issued a statement welcoming the initiative, emphasizing their DT120 candidate for GAD and MDD
• The biotech has delivered returns exceeding 300% over the trailing year and reached a 52-week peak at $25.63
• Analyst consensus points to a Strong Buy rating with a mean price objective of $38.75 — implying approximately 70% potential appreciation

Shares of Definium Therapeutics experienced a notable rally on Monday following President Donald Trump’s signing of an Executive Order designed to accelerate the development of psychedelic-based treatments for mental health conditions.

The presidential directive emphasized the therapeutic promise of psychedelics for conditions such as depression, anxiety, and suicide risk. It further directed the FDA to eliminate regulatory obstacles that have historically delayed progress in this research area.

DFTX shares climbed 13.71% during premarket activity. Over the past year, the stock has delivered gains surpassing 300%, touching a new 52-week high of $25.63 during Monday’s session.

Definium CEO Rob Barrow released a statement praising the administration’s action. He expressed that the company “applauds the Administration’s recognition that psychedelic medicines may represent meaningful new treatment options.” Barrow highlighted their flagship asset, DT120, a lysergide tartrate formulation in development for Generalized Anxiety Disorder and Major Depressive Disorder.

The White House order also drew attention to veteran suicide statistics, noting that approximately 6,000 veterans die by suicide annually in the United States. The directive referenced increased suicide rates during pandemic-era restrictions, which approached historical highs. The administration positioned psychedelic therapeutics as a potential solution to these challenges.

Despite robust percentage gains in premarket trading, volume remained modest. Approximately 146,000 shares traded by the time of reporting, compared to a three-month average daily volume of roughly 1.68 million.

Wall Street Outlook and Price Projections

Analysts maintain bullish sentiment on the stock. DFTX holds a Strong Buy consensus rating supported by 12 Buy recommendations issued in the last three months. The mean analyst price target stands at $38.75, suggesting potential upside of approximately 70% from current trading levels.

Stifel launched coverage with a Buy rating, highlighting a favorable probability of success for DT120 in treating GAD. Piper Sandler initiated with an Overweight rating, describing DT120 as a “best-in-class opportunity” within the neuroplastogen therapeutic category.

Phase 3 clinical trial results for DT120 in Generalized Anxiety Disorder are anticipated in early third quarter 2026. The company’s next earnings report is scheduled for release in approximately 17 days.

Industry and Market Overview

Generalized Anxiety Disorder impacts over 10% of U.S. adults during any three-year interval, based on research published in the Journal of Mood and Anxiety Disorders. The prevalence of GAD in the United States registered at 6.6% during 2023.

DFTX shares have advanced 69.38% since the beginning of the year and currently command a market capitalization near $2.26 billion.

According to InvestingPro analysis, the stock may be trading below intrinsic Fair Value estimates, though the Relative Strength Index currently signals overbought conditions. With a beta coefficient of 2.56, the stock exhibits significant volatility relative to broader market movements.

The stock’s 52-week low was recorded at $5.45. Current trading levels hover around $25.78.

The post Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump’s Psychedelic Research Order appeared first on Blockonomi.